Sonoma Biotherapeutics
Facts
- HQ
- South San Francisco, California, US
- Sectors
- Biotechnology Research
- Founded
- 2019
- Employees
- 61
- Stage
- Clinical-stage
Sonoma Biotherapeutics Launches 83,000-Sq-Ft Seattle Waterfront R&D Center for Autoimmune Disease Research
Sonoma Biotherapeutics opened a new 83,000-square-foot R&D center on Seattle's waterfront to consolidate its staff and advance early-stage autoimmune disease research using regulatory T cells. The facility accommodates 65 scientists and is equipped with flexible lab spaces and advanced scientific equipment.
Pacific Northwest Life Sciences Update: Talus Bioscience Raises $9.75M, Kineta Merges with Yumanity, UW’s David Baker Launches Charm Therapeutics
Recent Pacific Northwest life sciences news includes Talus Bioscience raising $9.75 million, Kineta going public via merger with Yumanity, and UW's David Baker launching Charm Therapeutics. Key partnerships involve TwinStrand and Singular Genomics developing rare gene variant tests, and Umoja Biopharma partnering with TreeFrog Therapeutics for stem cell therapies.
CBRE: U.S. life-sciences VC tops $30B; Seattle-area firms raise $898M amid scarce lab space
A CBRE report shows U.S. life sciences venture funding topped $30 billion for the 12 months ending September 2021, driving strong demand for lab space and record capital raises in Seattle-area companies that pulled in $898 million during that period. Washington state also saw rising life-science employment and multiple biotech IPOs in 2021, including large offerings from Sana Biotechnology, Absci and Icosavax.
